Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trasylol prompts Bayer study review changes

Executive Summary

Firm is amending its process for reviewing drug studies in light of conclusions by an independent reviewer that its current procedures were partly to blame for Bayer's failure to disclose Trasylol data to FDA prior to a September 2006 advisory committee meeting. Bayer's Protocol Review Committee oversight will be extended to company-sponsored or co-development studies in six categories, including pharmacoepidemiological studies such as the i3 Drug Safety study of Trasylol, company says in an Aug. 17 press release. Bayer came under fire last year when it was revealed two employees knew of preliminary results of the i3 study but did not disclose them before the agency's Cardiovascular and Renal Drugs Advisory Committee meeting, which was convened to review Trasylol's safety. Overall, the report by William Taylor, a partner with Zuckerman Spaeder, exonerates Bayer staff and blames the issue on operational factors and "human error"...

You may also be interested in...



Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials

To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.

Unprecedented To Lawful: Regulatory Precedent Needed For Cannabinoids’ Use In Supplements?

“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”

UsernamePublicRestriction

Register

OM009724

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel